Display options
Cite
McAdam-Marx C, Gaebler JA, Bellows BK, et al. Contemporary management of patients with Type 2 diabetes. Expert Rev Cardiovasc Ther. 2010;8(6):767-70doi: 10.1586/erc.10.62.
McAdam-Marx, C., Gaebler, J. A., Bellows, B. K., & Brixner, D. I. (2010). Contemporary management of patients with Type 2 diabetes. Expert review of cardiovascular therapy, 8(6), 767-70. https://doi.org/10.1586/erc.10.62
McAdam-Marx, Carrie, et al. "Contemporary management of patients with Type 2 diabetes." Expert review of cardiovascular therapy vol. 8,6 (2010): 767-70. doi: https://doi.org/10.1586/erc.10.62
McAdam-Marx C, Gaebler JA, Bellows BK, Brixner DI. Contemporary management of patients with Type 2 diabetes. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):767-70. doi: 10.1586/erc.10.62. PMID: 20528633.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Cardiovasc Ther. 2010 Jun;8(6):767-70. doi: 10.1586/erc.10.62.

Contemporary management of patients with Type 2 diabetes.

Expert review of cardiovascular therapy

Carrie McAdam-Marx, Julia A Gaebler, Brandon K Bellows, Diana I Brixner

Affiliations

  1. University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA. [email protected]

PMID: 20528633 DOI: 10.1586/erc.10.62

Abstract

EVALUATION OF: Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with Type 2 diabetes. Am. J. Hypertens. 23(3), 334-339 (2010). Type 2 diabetes is often accompanied by other comorbidities that similarly contribute to cardiovascular risk. New antidiabetics including glucagon-like peptide-1 agonists have demonstrated blood glucose control in patients with Type 2 diabetes with a low risk of hypoglycemia and a favorable impact on bodyweight. Evidence suggests that these agents may convey benefit in managing additional cardiovascular risks. In a recent pooled analysis of randomized controlled trial data, Okerson et al. identified a significant reduction in systolic blood pressure in patients treated with exenatide, particularly in patients with elevated systolic blood pressure. This study provides further evidence that glucagon-like peptide-1 agonists confer therapeutic benefit for managing Type 2 diabetes while also managing other cardiovascular risk factors.

Publication Types